{"organizations": [], "uuid": "b91f9980a1f455b4466b832710bc93a79540d9ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ardelyx-successfully-completes-t3m/brief-ardelyx-successfully-completes-t3mpo-3-safety-extension-study-of-tenapanor-for-ibs-c-idUSFWN1OY0BF", "country": "US", "domain_rank": 408, "title": "BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T13:38:00.000+02:00", "replies_count": 0, "uuid": "b91f9980a1f455b4466b832710bc93a79540d9ec"}, "author": "", "url": "https://www.reuters.com/article/brief-ardelyx-successfully-completes-t3m/brief-ardelyx-successfully-completes-t3mpo-3-safety-extension-study-of-tenapanor-for-ibs-c-idUSFWN1OY0BF", "ord_in_thread": 0, "title": "BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C", "locations": [], "entities": {"persons": [], "locations": [{"name": "tenapa", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters staff  jan", "sentiment": "none"}, {"name": "ardelyx inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 38 AM / in 11 minutes BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C Reuters Staff \nJan 3 (Reuters) - Ardelyx Inc: \n* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C \n* ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO‘S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​ \n* ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T13:38:00.000+02:00", "crawled": "2018-01-03T13:57:12.016+02:00", "highlightTitle": ""}